4263 Stock Overview
SUSMED,Inc. develops and sells therapeutic applications in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SUSMED,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥522.00 |
| 52 Week High | JP¥1,823.00 |
| 52 Week Low | JP¥504.00 |
| Beta | 1.73 |
| 1 Month Change | 0.19% |
| 3 Month Change | -26.79% |
| 1 Year Change | -63.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4263 | JP Healthcare Services | JP Market | |
|---|---|---|---|
| 7D | -4.7% | -6.1% | -2.2% |
| 1Y | -63.7% | -38.5% | 29.7% |
Return vs Industry: 4263 underperformed the JP Healthcare Services industry which returned -38.5% over the past year.
Return vs Market: 4263 underperformed the JP Market which returned 29.7% over the past year.
Price Volatility
| 4263 volatility | |
|---|---|
| 4263 Average Weekly Movement | 8.8% |
| Healthcare Services Industry Average Movement | 6.4% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4263's share price has been volatile over the past 3 months.
Volatility Over Time: 4263's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Taro Ueno | www.susmed.co.jp |
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease.
SUSMED,Inc. Fundamentals Summary
| 4263 fundamental statistics | |
|---|---|
| Market cap | JP¥8.95b |
| Earnings (TTM) | JP¥49.00m |
| Revenue (TTM) | JP¥732.00m |
178.2x
P/E Ratio11.9x
P/S RatioIs 4263 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4263 income statement (TTM) | |
|---|---|
| Revenue | JP¥732.00m |
| Cost of Revenue | JP¥9.00m |
| Gross Profit | JP¥723.00m |
| Other Expenses | JP¥674.00m |
| Earnings | JP¥49.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 2.93 |
| Gross Margin | 98.77% |
| Net Profit Margin | 6.69% |
| Debt/Equity Ratio | 0% |
How did 4263 perform over the long term?
See historical performance and comparison